First evidence that combination therapies can improve response to checkpoint blockade in HCC has been provided by a phase III study investigating the combination of the checkpoint inhibitor atezolizumab (anti-programmed death ligand (PD-L) 1) and bevazicumab [anti-vascular endothelial growth factor (VEGF)], which reported outcomes superior to Sorafenib in HCC (12). Here, VEGFA is linked to hepatocellular carcinoma.